Logo image of ALHYP.PA

HIPAY GROUP SA (ALHYP.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALHYP - FR0012821916 - Common Stock

8.46 EUR
+0.08 (+0.95%)
Last: 12/5/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ALHYP scores 2 out of 10 in our fundamental rating. ALHYP was compared to 54 industry peers in the Financial Services industry. Both the profitability and financial health of ALHYP have multiple concerns. ALHYP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

ALHYP had positive earnings in the past year.
In multiple years ALHYP reported negative net income over the last 5 years.
ALHYP had a positive operating cash flow in 4 of the past 5 years.
ALHYP.PA Yearly Net Income VS EBIT VS OCF VS FCFALHYP.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

ALHYP's Return On Assets of 0.55% is in line compared to the rest of the industry. ALHYP outperforms 43.40% of its industry peers.
Looking at the Return On Equity, with a value of 3.06%, ALHYP is in line with its industry, outperforming 54.72% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.43%, ALHYP is in the better half of the industry, outperforming 71.70% of the companies in the same industry.
Industry RankSector Rank
ROA 0.55%
ROE 3.06%
ROIC 6.43%
ROA(3y)-0.13%
ROA(5y)-0.88%
ROE(3y)-2.18%
ROE(5y)-5.3%
ROIC(3y)N/A
ROIC(5y)N/A
ALHYP.PA Yearly ROA, ROE, ROICALHYP.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

Looking at the Profit Margin, with a value of 1.54%, ALHYP is in line with its industry, outperforming 43.40% of the companies in the same industry.
ALHYP has a Operating Margin (6.25%) which is in line with its industry peers.
The Gross Margin of ALHYP (52.12%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ALHYP has grown nicely.
Industry RankSector Rank
OM 6.25%
PM (TTM) 1.54%
GM 52.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.74%
GM growth 5Y1.61%
ALHYP.PA Yearly Profit, Operating, Gross MarginsALHYP.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ALHYP is creating some value.
ALHYP has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALHYP has about the same amount of shares outstanding.
The debt/assets ratio for ALHYP is higher compared to a year ago.
ALHYP.PA Yearly Shares OutstandingALHYP.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
ALHYP.PA Yearly Total Debt VS Total AssetsALHYP.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 0.37, we must say that ALHYP is in the distress zone and has some risk of bankruptcy.
ALHYP has a worse Altman-Z score (0.37) than 67.92% of its industry peers.
ALHYP has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
ALHYP has a Debt to Equity ratio (0.32) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z 0.37
ROIC/WACC1.07
WACC5.99%
ALHYP.PA Yearly LT Debt VS Equity VS FCFALHYP.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 1.01 indicates that ALHYP should not have too much problems paying its short term obligations.
ALHYP has a Current ratio of 1.01. This is in the lower half of the industry: ALHYP underperforms 69.81% of its industry peers.
A Quick Ratio of 1.01 indicates that ALHYP should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.01, ALHYP is not doing good in the industry: 67.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
ALHYP.PA Yearly Current Assets VS Current LiabilitesALHYP.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

3

3. Growth

3.1 Past

ALHYP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -86.08%.
ALHYP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.77%.
Measured over the past years, ALHYP shows a quite strong growth in Revenue. The Revenue has been growing by 16.33% on average per year.
EPS 1Y (TTM)-86.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.06%
Revenue 1Y (TTM)9.77%
Revenue growth 3Y11.26%
Revenue growth 5Y16.33%
Sales Q2Q%3.69%

3.2 Future

The Earnings Per Share is expected to decrease by -14.72% on average over the next years. This is quite bad
ALHYP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.47% yearly.
EPS Next Y-54.26%
EPS Next 2Y-27.93%
EPS Next 3Y-14.72%
EPS Next 5YN/A
Revenue Next Year3.23%
Revenue Next 2Y4.22%
Revenue Next 3Y4.47%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALHYP.PA Yearly Revenue VS EstimatesALHYP.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
ALHYP.PA Yearly EPS VS EstimatesALHYP.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1 -1.5

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 38.45, the valuation of ALHYP can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ALHYP is on the same level as its industry peers.
ALHYP's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.49.
A Price/Forward Earnings ratio of 12.26 indicates a correct valuation of ALHYP.
The rest of the industry has a similar Price/Forward Earnings ratio as ALHYP.
When comparing the Price/Forward Earnings ratio of ALHYP to the average of the S&P500 Index (23.69), we can say ALHYP is valued slightly cheaper.
Industry RankSector Rank
PE 38.45
Fwd PE 12.26
ALHYP.PA Price Earnings VS Forward Price EarningsALHYP.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALHYP is valued a bit cheaper than the industry average as 71.70% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.19
ALHYP.PA Per share dataALHYP.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

ALHYP's earnings are expected to decrease with -14.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.93%
EPS Next 3Y-14.72%

0

5. Dividend

5.1 Amount

ALHYP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

HIPAY GROUP SA

EPA:ALHYP (12/5/2025, 7:00:00 PM)

8.46

+0.08 (+0.95%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryFinancial Services
Earnings (Last)11-04 2025-11-04
Earnings (Next)04-09 2026-04-09
Inst Owners0.45%
Inst Owner ChangeN/A
Ins Owners50.11%
Ins Owner ChangeN/A
Market Cap53.38M
Revenue(TTM)75.63M
Net Income(TTM)1.16M
Analysts84.44
Price Target17.34 (104.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-11.94%
EPS NY rev (3m)-38.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.65%
Revenue NY rev (3m)-3.65%
Valuation
Industry RankSector Rank
PE 38.45
Fwd PE 12.26
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB N/A
EV/EBITDA 7.19
EPS(TTM)0.22
EY2.6%
EPS(NY)0.69
Fwd EY8.16%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS11.98
BVpS5.86
TBVpS-1.54
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.39
Profitability
Industry RankSector Rank
ROA 0.55%
ROE 3.06%
ROCE 8.75%
ROIC 6.43%
ROICexc 8.21%
ROICexgc N/A
OM 6.25%
PM (TTM) 1.54%
GM 52.12%
FCFM N/A
ROA(3y)-0.13%
ROA(5y)-0.88%
ROE(3y)-2.18%
ROE(5y)-5.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.74%
GM growth 5Y1.61%
F-ScoreN/A
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA 1.29
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z 0.37
F-ScoreN/A
WACC5.99%
ROIC/WACC1.07
Cap/Depr(3y)82.18%
Cap/Depr(5y)97.59%
Cap/Sales(3y)5.73%
Cap/Sales(5y)6.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.06%
EPS Next Y-54.26%
EPS Next 2Y-27.93%
EPS Next 3Y-14.72%
EPS Next 5YN/A
Revenue 1Y (TTM)9.77%
Revenue growth 3Y11.26%
Revenue growth 5Y16.33%
Sales Q2Q%3.69%
Revenue Next Year3.23%
Revenue Next 2Y4.22%
Revenue Next 3Y4.47%
Revenue Next 5YN/A
EBIT growth 1Y-25.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15%
EBIT Next 3Y9.49%
EBIT Next 5YN/A
FCF growth 1Y66.33%
FCF growth 3Y33.78%
FCF growth 5YN/A
OCF growth 1Y34.3%
OCF growth 3Y5.28%
OCF growth 5Y82.77%

HIPAY GROUP SA / ALHYP.PA FAQ

What is the ChartMill fundamental rating of HIPAY GROUP SA (ALHYP.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALHYP.PA.


Can you provide the valuation status for HIPAY GROUP SA?

ChartMill assigns a valuation rating of 3 / 10 to HIPAY GROUP SA (ALHYP.PA). This can be considered as Overvalued.


What is the profitability of ALHYP stock?

HIPAY GROUP SA (ALHYP.PA) has a profitability rating of 3 / 10.


How financially healthy is HIPAY GROUP SA?

The financial health rating of HIPAY GROUP SA (ALHYP.PA) is 2 / 10.


Can you provide the expected EPS growth for ALHYP stock?

The Earnings per Share (EPS) of HIPAY GROUP SA (ALHYP.PA) is expected to decline by -54.26% in the next year.